Surrozen, Inc. SRZNW
Set alert
As of Aug 6, 10:43 AM ET
- YTD
- -80.81%
- 1 year
- -80.81%
- Open
- 0.009
- Prev close
- 0.0015
- Mkt cap
- 11.22K
- Vol
- 26.47K
- Avg vol
- 0
- EPS
- -5.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0015
- High
- 0.0015
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.02
- EPS (TTM)
- -5.70
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 10.00M
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 31.01M
- Total debt
- 1.53M
- Return on equity
- -173.59%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Surrozen, Inc.
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- surrozen.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on SRZNW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 25.95% | 833,333 | 24.92K | Sep 29, 2024 |
| Bridger Management LLC | 14.53% | 466,666 | 13.95K | Sep 29, 2024 |
| California, University of-Regents | 6.74% | 216,540 | 6.47K | Sep 29, 2024 |
| Euclidean Capital Llc | 5.32% | 170,833 | 5.11K | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 5.19% | 166,666 | 4.98K | Sep 29, 2024 |
| Perceptive Advisors Llc | 5.19% | 166,666 | 4.98K | Sep 29, 2024 |